<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063383</url>
  </required_header>
  <id_info>
    <org_study_id>Clinical Characteristics PCOS</org_study_id>
    <nct_id>NCT05063383</nct_id>
  </id_info>
  <brief_title>Analysis of Clinical Characteristics and Study of Diagnostic Markers in Patients With Polycystic Ovary Syndrome</brief_title>
  <official_title>Analysis of Clinical Characteristics and Study of Diagnostic Markers in Patients With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators collected clinical data and serum samples of patients with polycystic ovary&#xD;
      syndrome in this study, used statistical software such as SPSS for data analysis, and used&#xD;
      experimental techniques such as ELISA to detect serum samples, aiming to explore the&#xD;
      relationship between the body anthropometry, glucose and lipid metabolism, gonadal hormones&#xD;
      and body fat distribution in patients with polycystic ovary syndrome and to discovery new&#xD;
      biomarkers and promote the realization of more accurate personalized medicine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic markers of PCOS patients</measure>
    <time_frame>baseline</time_frame>
    <description>Fibrinogen-like-protein 1 (FGL1), is a novel hepatokine that plays an important role in hepatic steatosis, insulin resistance and obesity. There is no maximum or minimum value for this parameter and the higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body mass index ,BMI</measure>
    <time_frame>baseline</time_frame>
    <description>BMI=weight(kg)/height(m)^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist/hip Ratio,WHR</measure>
    <time_frame>baseline</time_frame>
    <description>WHR=Waist Circumference(cm)/Hip Circumference(cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of menstruation in the last year</measure>
    <time_frame>baseline</time_frame>
    <description>physiological parameter,the total number of menstrual periods in the last year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferriman-Gallwey score</measure>
    <time_frame>baseline</time_frame>
    <description>The minimum value of Ferriman-Gallwey score is 0 and the maximum value is 44. An Ferriman-Gallwey score greater than or equal to 6 is considered to be a clinical manifestation of androgen excess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>baseline</time_frame>
    <description>Homeostatic model assessment insulin resistance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of sex hormones</measure>
    <time_frame>baseline</time_frame>
    <description>total testosterone (nmol/L), Free testosterone (nmol/L) and SHBG (nmol/L),LH, luteinizing hormone; FSH, follicle-stimulating hormone; DHEAS, dehydroepiandrosterone;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of different glucose and insulin metabolic profiles</measure>
    <time_frame>baseline</time_frame>
    <description>FBG, fasting blood-glucose; PBG, postprandial blood-glucose; FINS, fasting serum insulin; PINS, postprandial insulin;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of different hepatic metabolic profiles</measure>
    <time_frame>baseline</time_frame>
    <description>ALT, alanine aminotransferase; AST, aspartate aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of different renal metabolic profiles</measure>
    <time_frame>baseline</time_frame>
    <description>UA, Uric acid; CR, Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of different lipid metabolic profiles</measure>
    <time_frame>baseline</time_frame>
    <description>LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; TC,Total Cholesterol (mmol/L); TG, Triglyceride (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 22，IL-22</measure>
    <time_frame>baseline</time_frame>
    <description>The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6，IL-6</measure>
    <time_frame>baseline</time_frame>
    <description>IL-6. The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8， IL-8</measure>
    <time_frame>baseline</time_frame>
    <description>The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor， TNF</measure>
    <time_frame>baseline</time_frame>
    <description>The factor reflects that the organism is in an inflammatory state. There is no maximum or minimum value for the factor and the higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemerin</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>omentin-1</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leptin</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBP-4</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adiponectin</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine. The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resistin</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visfatin</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apelin</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaspin.</measure>
    <time_frame>baseline</time_frame>
    <description>A adipocytokine.The factor is expressed in adipose tissue and is related to specific adipose tissue function.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>PCOS</arm_group_label>
    <description>Oligomenorrhea/amenorrhea&#xD;
Clinical androgen excess or biochemical androgen excess&#xD;
Polycystic ovary showed by gynecological ultrasound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOPCOS</arm_group_label>
    <description>not meet Rotterdam standards</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This study does not involve any interventions</intervention_name>
    <description>This study does not involve any interventions</description>
    <arm_group_label>NOPCOS</arm_group_label>
    <arm_group_label>PCOS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Polycystic ovary syndrome (PCOS) is a common dis-order in women that is characterized by&#xD;
        hyperandro-genism (that is, evidence of excess male hormone or androgen effect; clinically,&#xD;
        such as hirsut-ism, and/or biochemically, such as hyperandrogen aemia or excess levels of&#xD;
        androgen), ovulatory dysfunction (including menstrual dysfunction) and polycystic ovarian&#xD;
        morphology (PCOM; an excessive number of preantral follicles in the ovaries). The clinical&#xD;
        presenta-tion is heterogeneous and can be categorized in several phenotypes. Metabolic&#xD;
        abnormalities, mainly insulin resistance and compensatory hyper-insulinaemia, are evident&#xD;
        in a majority of affected individuals. Women with PCOS have an increased risk for&#xD;
        meta-bolic abnormalities and T2DM, infertility, obstetrical complications, endometrial&#xD;
        cancer and mood dis orders. These women also probably have an increased risk for&#xD;
        cardiovascular and cerebrovascular events, venous thromboembolism and ovarian cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged 18- 45;&#xD;
&#xD;
          -  Meet Rotterdam criteria;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or have a pregnancy plan within six months;&#xD;
&#xD;
          -  Congenital adrenocortical hyperplasia;&#xD;
&#xD;
          -  Hyperprolactinemia;&#xD;
&#xD;
          -  Hyperthyroidism or hypothyroidism;&#xD;
&#xD;
          -  Abnormal liver function (≥ 3 times of the upper limit of normal range);&#xD;
&#xD;
          -  Abnormal renal function (GFR&lt;60ml/min/1.73m2);&#xD;
&#xD;
          -  Adrenal or ovarian tumors secreting androgens;&#xD;
&#xD;
          -  Used contraceptives, metformin, GLP-1RA, pioglitazone and contraceptives in the last 3&#xD;
             month.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Qu, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Shang hai Tenth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manna Zhang, Dr</last_name>
    <phone>（86）66301004</phone>
    <email>mannazhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tenth People' Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Manna</investigator_full_name>
    <investigator_title>Director, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>clinical characteristics</keyword>
  <keyword>new biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

